CD44 and prostate carcinoma: Based on the RNA-seq of 499 tumors from the prostate cancer patient cohort in The Cancer Genome Atlas (TCGA), the alteration of 21 genes, upregulation of 13 genes (e.g., ITGA2B, FYN, and PTK3), and downregulation of 8 genes (e.g., PTEN, CD44, and ARAF) in the Src signaling pathway were associated with tumors diagnosed with high Gleason scores 9–10 (Figure S8A).